Solid Biosciences Inc. (SLDB) Fair Value 2026

SLDB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Solid Biosciences Inc. (SLDB) trades at $9.77. QOC: 4.9/10. Value Trap Risk: 35/100 (LOW). 0/13 models active.

Key Facts

Ticker
SLDB
Price
$9.77
Quality Score
4.9/10
Value Trap Risk
35/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.9/10 signals weak fundamentals

What Fair Value Does Each Model Give SLDB?

0 Intrinsic Value Models vs. Current Price ($9.77)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Solid Biosciences Inc. (SLDB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Solid Biosciences Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About SLDB?

0 of 13 models are currently active for SLDB. See which stocks rank higher →

How Does SLDB Rank in Biotechnology?

Among 625 Biotechnology stocks, SLDB ranks #345 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Solid Biosciences Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating SLDB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SLDB a Value Trap?

CirclFi's Value Trap algorithm assigns SLDB a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Solid Biosciences Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Solid Biosciences Inc.'s fundamental quality profile registers 4.9/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SLDB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Solid Biosciences Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

AIMAIM ImmunoTech Inc.QOC 4.9AVXLAnavex Life Sciences Corp.QOC 4.9LXEOLexeo Therapeutics, Inc.QOC 4.9RCKTRocket Pharmaceuticals, Inc.QOC 4.9OSRHOSR Health, Inc.QOC 4.9YARWYarrow Bioscience IncQOC 4.9GUTSFractyl Health, Inc.QOC 4.2NVAXNovavax, Inc.QOC 7.7OTLCOncotelic Therapeutics, Inc.QOC 5.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: AIM · AVXL · LXEO · RCKT · OSRH · YARW · GUTS · NVAX · OTLC · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SLDB?

6 companies across all industries closest to SLDB’s Quality of Company score of 4.9/10.

HONAHoneywell Aerospace Inc.QOC 4.9PRTPermRock Royalty TrustQOC 4.9BRRProCap Financial, Inc.QOC 4.9SBETSharplink, Inc.QOC 4.9BGRBlackRock Energy and Resources TrustQOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HONA · PRT · BRR · SBET · BGR · NVDA

Where Does SLDB Sit in CirclFi's Biotechnology Rankings?

SLDB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Solid Biosciences Inc.’s Valuation?

What is Solid Biosciences Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Solid Biosciences Inc. (SLDB). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SLDB overvalued or undervalued right now?

At $9.77, 0 of 0 active models suggest SLDB may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Solid Biosciences Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.9 mean for SLDB?

Solid Biosciences Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on SLDB?

CirclFi analyzes SLDB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is SLDB a value trap in 2026?

Solid Biosciences Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Solid Biosciences Inc. (SLDB) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SLDB/ · Methodology
Primary sources for this SLDB valuation
  • Financial statements: Solid Biosciences Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001707502) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SLDB as of ; valuations recomputed .